Adipose tissue-derived stromal vascular fraction in regenerative medicine: a brief review on biology and translation

Pablo Bora and Anish S. Majumdar

Abstract

Adipose/fat tissue provides an abundant source of stromal vascular fraction (SVF) cells for immediate administration and can also give rise to a substantial number of cultured, multipotent adipose-derived stromal cells (ADSCs). Recently, both SVF and ADSCs have gained wide-ranging translational significance in regenerative medicine. Initially used for cosmetic breast enhancement, this mode of treatment has found use in many diseases involving immune disorders, tissue degeneration, and ischaemic conditions. In this review, we try to address several important aspects of this field, outlining the biology, technology, translation, and challenges related to SVF- and ADSC-based therapies. Starting from the basics of SVF and ADSC isolation, we touch upon recently developed technologies, addressing elements of novel methods and devices under development for point-of-care isolation of SVF. Characterisation of SVF cells and ADSCs is also an evolving area and we look into unusual expression of CD34 antigen as an interesting marker for such purposes. Based on reports involving different cells of the SVF, we draw a potential mode of action, focussing on angiogenesis since it involves multiple cells, unlike immunomodulation which is governed predominantly by ADSCs. We have looked into the latest research, experimental therapies, and clinical trials which are utilising SVF/ADSCs in conditions such as multiple sclerosis, Crohn's disease, peripheral neuropathy, osteoarthritis, diabetic foot ulcer, and so forth. However, problems have arisen with regards to the lack of proper regulatory guidelines for such therapies and, since the introduction of US Food and Drug Administration draft guidelines and the Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) Act, the debate became more public with regards to safe and efficacious use of these cells.

Keywords: Regenerative medicine, Multipotent-stromal cells, Stromal vascular fraction, Point-of-care biomedical devices, CD34, Regulation of stem cell therapeutics

Background

Adipose-derived stem/stromal cells (ADSCs) were first characterised in 2001, and have since been widely studied and used as a major source of cells with regenerative potential, with characteristics similar to that of mesenchymal stem/stromal cells (MSCs) [1–4]. ADSCs are isolated as part of the aqueous fraction derived from enzymatic digestion of lipoaspirate (the product of liposuction). This aqueous fraction, a combination of ADSCs, endothelial precursor cells (EPCs), endothelial cells (ECs), macrophages, smooth muscle cells, lymphocytes, pericytes, and pre-adipocytes among others, is what is known as the stromal vascular fraction (SVF).

ADSCs, like MSCs, have shown promise in regenerative and reconstructive medicine [5–8]. Recent advances in the area of tissue regeneration have put SVF on a par and at times even above ADSCs [9–17]. For instance, in a study of erectile function in a rat model of cavernous nerve injury, SVF treatment showed superior statistically significant results compared to ADSC treatment alone, especially in smooth muscle/collagen ratio and in endothelial cell content [12]. The advantage of SVF over ADSCs is believed to be in two fundamental areas. Firstly, although similar in properties such as

* Correspondence: anish.majumdar@stempeutics.com

1 Stempeutics Research Private Limited, Akshay Tech Park, # 72&73, 2nd Floor, EPIP Zone, Phase 1, Whitefield, Bangalore 560066, India

Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
immunomodulation, anti-inflammatory, angiogenesis, and so forth, the distinctive, heterogeneous cellular composition of SVF may be responsible for the better therapeutic outcome observed in comparative animal studies [9–12]. Secondly, unlike ADSCs, SVF is much more easily acquired, without the need for any cell separation or culturing conditions. Thus, the therapeutic cellular product is instantaneously obtained and has minimal contact with reagents making it comparatively safer and subject to the fulfilment of lesser regulatory criteria. It should be noted that, whereas ADSCs find utility in both allogeneic and autologous treatments, SVF, owing to the presence of various cell types known to cause immunological rejection, is suitable for autologous treatments only.

Although almost all ADSCs are derived from the white adipose tissue (WAT), as covered in this review, the identification of progenitor cells in brown adipose tissue (BAT) of adult humans is fascinating and worth a mention [18, 19]. Termed as BADSCs (brown adipose-derived stem cells), these have been isolated from BAT deposits present in relatively inaccessible regions such as the mediastinum, and are capable of differentiating to metabolically active BA cells with differences in surface antigen expression as compared to WAT-originating ADSCs [18]. Current understanding of WAT and BAT define these cells with distinct functionalities, and thus translational avenues for ADSCs from either source should be compared to identify specific therapeutic targets and potential advantage of one over the other. Understanding of the molecular mechanisms behind either cell fate and the possibility of interconversion are interesting avenues of research with basic and translational implications [20, 21].

Despite the potential of SVF in regenerative medicine there are challenges to overcome. First is isolation of SVF, which needs a specialised infrastructure such as a clean room facility, equipment, reagents, and technical capabilities. These conditions limit the reach of SVF to only major hospitals in tier 1/2 cities, especially in a country such as India. In this regard, the up and coming point-of-care biomedical devices which can take lipoaspirate as their input and produce sterile, injectable SVF intended for in vitro expansion [7, 30].

Secondly, the method of isolating SVF is a vital roadblock in the approved use of SVF for therapeutic applications. Digestion of lipoaspirate is achieved by collagenase, and the presence of collagenase in the injectable product does not bode well with regulatory authorities such as the US Food and Drug Administration (FDA) [3]. Consequently, alternative methods are being explored with some encouraging outcomes [22–25]. Finally, characterisation of the regenerative cells of SVF has not reached a wide consensus. Organisations such as the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society of Cellular Therapy (ISCT) have been updating the surface antigen-based definition of SVF cells, where CD34 antigen, primarily associated with haematopoietic stem cells (HSCs), became an important marker of regenerative, MSC-like cells of the SVF [1, 26, 27].

In this review, using the broader topics of isolation and characterisation of SVF, we will touch upon some of the challenges and innovations in the field and comment upon the future of SVF.

**Isolation of SVF**

**Enzymatic isolation of SVF**
The most widely used technique for the isolation of SVF from lipoaspirate is by digestion of the fatty portion of the lipoaspirate with collagenase, separating the contents into two distinct phases: the floating mature adipocytes fraction, and the cellular components of interest in the lower aqueous fraction [17, 28]. This separation can be enhanced by centrifugation; nevertheless, comparable separation can be achieved by gravity-based phase separation and filtration [29]. Although centrifugation is more efficient, it will also pellet down all the cells present, while filtration can be designed to capture only the important cell types based on size, thus enriching the specific cellular cocktail.

Centrifugation of the aqueous fraction yields a reddish pellet which contains SVF cells. Erythrocytes, a major contaminant present in the SVF pellet, can be lysed to isolate a purer population of ADSCs and/or SVF cells if intended for in vitro expansion [7, 30].

**Non-enzymatic isolation of SVF**
In view of the regulatory questions relating to enzymatic isolation, it is important to look into alternative methods for isolating SVF and compare these with the conventional methods [3, 24, 25]. Most of these techniques involve mechanical agitation which breaks down the adipose tissue and releases the stromal cells. As expected, the cellular yield from mechanical procedures are much lower compared to enzymatic methods, as cells of the adipose tissue tightly bound by collagen will not be easily released by mechanical action alone [24].

A novel method of mechanical agitation was recently defined by Tonnard et al. [23]. The injectable product, termed “nanofat”, was obtained by emulsification and filtration of the lipoaspirate. Although termed as nanofat grafting, in effect no viable adipose cells survived the emulsification process, but the graft was rich in CD34+ ADSCs. The efficacy and properties of nanofat have been demonstrated in multiple case studies related to skin rejuvenation, scar healing, skin grafting for wound management, and treating vulvar lichen sclerosus (VLS), a chronic inflammatory disease of the anogenital area, and also by standard ADSC-related phenotypic and differentiation studies [23, 31, 32]. Owing to the simplicity of the technique, it might be amenable to scaling up by...
Automated devices for point-of-care isolation of SVF
The infrastructure, expertise, and consumables required for the conventional method of SVF isolation is not commonplace in most health-care facilities. Cosmetic surgery, being at the upper-end of medical expenditure, is the largest consumer of SVF and related products, but the actual scope is much wider [3]. Thus, it is unfortunate that the benefits of this very simple technology have not reached full potential. This gap can be overcome by automated, point-of-care biomedical devices, which can produce injectable SVF from liposapirate.

Such developments have been underway for quite some time, although mostly still in trial stages, with Cytori’s (San Diego, USA) Celution™ being the first system [33]. Currently, about 30 different automated and semi-automated systems are under development [22]. The technologies and methodologies used vary, with most opting for the tried and tested enzymatic process. Stempeutics (Bangalore, India) has developed one such system, Stempeutron™, the proof-of-concept of which was reported in SundarRaj et al. [29]. Stempeutron™ uses the more efficient and conventional enzymatic digestion method and gravity-enabled separation of fatty and aqueous fraction followed by filtration of the aqueous fraction to achieve SVF isolation and concentration.

Since Stempeutron™ uses filtration we wanted to know the physical dimensions of SVF cells. As such, a list of cell sizes was not found while searching through the literature for this review and we resorted to mining for individual reports of cell size, surface area, and volume measurements. Table 1 summarises available cell diameter information accumulated from various reports [34–45]. The filtration system in Stempeutron™ is capable of capturing the majority of the therapeutically important cell types (Table 1) [3, 29]. Future developments might enable size-based enrichment of specific cellular populations, targeted towards specific diseases.

Characterisation of SVF
Criteria for characterising the cellular contents of SVF using surface antigen (cluster of differentiation (CD)) combinations is an evolving area of research as, within certain generally accepted norms, it differs between laboratories. A list of commonly used positive and negative markers identifying different cellular populations of SVF is provided in Table 1 [1, 26, 29]. Considering the variables present in isolation of SVF, such as the age of the patient, downstream processing, and so forth, the diversity observed between samples is quite understandable. However, if there is a relationship between the different ratios of cellular components present in SVF with its efficacy towards specific ailments, one might be able to come up with an optimum composition corresponding to the highest therapeutic efficacy. Traktuev et al. demonstrated that certain factors produced by ADSCs such as vascular endothelial growth factor (VEGF) help in migration, and that better survival of EPCs and correspondingly platelet-derived growth factors (PDGF)-BB produced by EPCs enable ADSCs to proliferate and migrate [46, 47]. They also provide proof of physical interaction between ADSCs and ECs in which EPCs form a stable tubular, vasculature-like structure with support from ADSCs, both in vitro and in vivo [47]. This information along with some other articles has been used to draw up a schematic in Fig. 1 for the action of SVF, focussing on the interaction between ADSCs and EPCs [46–49].

Table 1 Important components of SVF, respective sizes, and surface markers

| Cell types of the SVF | Cell size range (in µm)* | Molecular markers† [1, 26, 29] |
|-----------------------|-------------------------|-------------------------------|
|                       |                         | Positive                      | Negative                     |
| ADSC                  | ~10–25 µm and reported up to 200+ µm in culture [34–36] | CD34, CD73, CD13, CD90, CD105, CD29 | CD31, CD45, CD144 |
| EPC                   | ~7–8 µm (smallest defined) [37] | CD34, CD31, CD133, CD146 | CD45 |
| EC                    | ~10–30 µm [38] | CD31, FVIII | CD34 |
| T regulatory cells    | ~7–12 µm [39, 40] | CD4, CD25, Foxp3, CD8 | – |
| Macrophages           | ~20 µm [41] | CD45, CD14, CD34, CD206 | – |
| Smooth muscle cells   | ~3–20 µm in width and 20–500 µm in length [42, 43] | Smooth muscle actin (SMA) | – |
| Pericytes             | Up to ~70 µm in length [44] | CD146, CD90, CD73, CD44, CD29, CD13 | CD34, CD45, CD56 |
| Pre-adipocytes        | ~10 µm [45] | CD34 | CD45, CD31, CD146 |

* Diameter; unless mentioned otherwise
† The Table captures the approximate range of cell sizes as reported in different studies [34–45] and provides an overview of surface antigens for the respective cell type [1, 26, 29]. Includes surface or CD markers, cytoplasmic and nuclear factors
ADSC adipose-derived stem/stromal cells, EC endothelial cells, EPC endothelial precursor cells, SVF stromal vascular fraction.
ADSCs in SVF are currently defined to be positive for classical MSC markers such as CD73 and CD90, and express CD34 but not the pan-haematopoietic lineage marker CD45. CD34 is expressed by progenitors of haematopoietic and endothelial lineages as well, and in ADSCs it is expressed transiently up to about 8–12.

**Fig. 1** Potential mechanism of action of ADSCs and ECs present in SVF towards angiogenesis. Breakdown of adipose tissue releases many cell types, which together are termed SVF. The cells of the SVF can produce several bioactive soluble factors. ADSCs and EPCs, two important components of SVF, cross-talk via VEGF and PDGF-BB, respectively (among other components), to enable cell proliferation, homing towards injury, neovascularisation and other inter-connected outcomes. ADSC adipose-derived stromal cell, bFGF basic fibroblast growth factor, EC endothelial cell, EPC endothelial progenitor cell, GF growth factor, IGF-1 insulin-like growth factor-1, MMP matrix metalloproteinase, PDGF platelet-derived growth factor, RBC red blood cell, SVF stromal vascular fraction, VEGF vascular endothelial growth factor.
The curious case of CD34

ADSC research, being predominantly carried out using culture-expanded cells, has led to rather recent acceptance of CD34 as a marker for freshly isolated and native ADSCs. Thus, there remain interesting aspects of CD34 biology to be explored and understood. Firstly, CD34 expression has been associated with “stemness” in various systems including human ADSCs. A report by Suga et al. implied association of CD34 expression with naïveté, angiogenic gene expression, and greater replicative capacity [54]. Similar to HSCs, reversal of CD34 expression has also been observed in MSCs with a change in culture conditions, thus hinting that CD34 expression might be reversible [53, 54]. Maumus et al. demonstrated an inverse relationship between CD34 expression and in vitro expansion of ADSCs and provided evidence for CD34 being a niche-specific marker of human ADSCs [52]. Interestingly, they commented on the morphological features of ADSCs in vivo, that is having up to 80-μm long protrusions, capable of forming networks surrounding mature adipocytes; however, the scientific and anatomical reason for these structural features are poorly understood. Taking these into account has led to speculation that CD34 is a physiological niche-specific marker of immature/early progenitor cells which is lost in in-vitro conditions [52–56]. Scherberich et al. review CD34 biology in general and with regards to ADSCs in detail [56].

The second interesting aspect is the relationship between CD34 and hypoxia. Since CD34 might be a niche-specific marker of progenitors, it can be speculated that hypoxic conditions might have something to do with its expression. Hypoxia is related to maintenance of adult stem cells such as those in bone marrow and neural stem cells [57]. In MSCs, and also recently in ADSCs, hypoxic pre-conditioning/culturing has shown improved results with regards to proliferation, retention of transplant, angiogenesis, and modulation of angiogenic factors such as VEGF and interleukin (IL)-6, homing, and mobilisation-related characteristics of MSCs/ADSCs, and so forth [58–63]. It is important to note that the ADSC study specifically selected for CD34− cells to begin with and subsequently did not find any significant expression of CD34 in their hypoxically cultured cells [63]. On the other hand, there was a study which speculated that the CD34 gene might be transcriptionally regulated by hypoxia inducible factor 1 (HIF1). The researchers

| Table 2 | Overview of characteristics of native and culture expanded ADSCs |
|---------|---------------------------------------------------------------|
| Factors | Native ADSCs [52] | Culture-expanded ADSCs [1, 34–36, 46, 47, 52] |
| Cell surface markers | CD34, CD73, CD90, CD13 | CD73, CD90, CD13; (CD34 expression decreases and ceases with in vitro expansion) |
| Morphology | Branched, with up to 80-μm long protrusions forming a network surrounding mature adipocytes | Typical elongated, stromal cell shape, ~10–25 μm and reported to go up to 200 μm |
| Location | Both perivascular and stromal positions in situ | Not applicable |
| Functional characteristics | • Support adipose tissue growth. • Might differentiate to form mature adipocytes | • Facilitate and/or participate in angiogenesis. • Potential for differentiation to adipose, osteo-, and chondrogenic lineages. • Immunomodulatory properties. |

This table summarises important characteristics and differences between native and culture expanded ADSCs [1, 34–36, 46, 47, 52].

ADSC adipose-derived stem/stromal cell
observed that the concentration of oxygen in culture not only influenced the expression of CD34 but also that better maintenance of the antigen corresponded with more undifferentiated cells, which led them to hypothesise that CD34 and hypoxia play an important and inter-related function in maintenance of primitive stem cells of cord blood [64].

Such observations give a certain level of enigma; clearly CD34 and hypoxia are important factors in the maintenance of “stemness”, and it is also likely that CD34 expression is somehow related to hypoxic conditions in different stem or progenitor cell types. However, such a connection remains to be mechanistically studied in human ADSCs, or any other kind of MSCs for that matter. Such studies might provide evidence connecting CD34 with more naive/primitive stem cells, maintained in a hypoxic niche.

Current state in the clinic and laboratory
The first clinical applications of SVF were reported around 2007 to 2008 for cosmetic breast augmentation and also in the treatment of radiation injury post-radiotherapy in breast cancer patients [14, 65]. The Yoshimura group coined the term CAL, or cell-assisted lipotransfer, in 2008, where they enhanced fat grafts with SVF, demonstrating improved graft retention [14, 17]. Since these two early clinical reports from the last decade, there has been a many-fold increase in basic research and, consequently, many clinical trials are also now underway.

Searching www.ClinicalTrials.gov with keywords such as “SVF”, “Stromal vascular fraction”, “ADSC”, “Adipose stem cells”, and so forth, provides many hits. Although most of those studies are underway or recruiting at the time of this communication, interest has been rising with time. What is truly exciting is the breadth of conditions being targeted by SVF and ADSCs. Despite having properties like MSCs, the use of culture-expanded ADSCs has not reached similar consensus for allogeneic applications. However, ADSCs and SVF have been the preferred regenerative tools for use in autologous applications, and some of the major ones (along with case study references and/or ClinicalTrials.gov identification number) are listed in Table 3 [10, 14, 16, 23, 30, 31, 65–76]. Some other major ailments covered are pulmonary diseases, arterial and vascular diseases, graft versus host disease, Crohn’s disease, peripheral nerve regeneration, and so forth. Clinical areas where SVF and ADSCs are used do overlap to a substantial extent. Nevertheless, there are understandable differences between the two, but the few comparative pre-clinical and clinical studies available do not reach a unanimous conclusion. However, to summarise where the field stands as of now, a comparative overview of both modes with a few examples favouring either option is provided in Table 4 [9, 11, 12, 77].

A superficial glance at the treatments highlights the two most preferred pathways, that is employing the vasculogenic and the immunomodulatory properties. We are yet to fully explore the multipotent properties of SVF cells which will only increase the breadth of their application. One recent example of enhanced osteoinduction by using SVF for dental implant surgery in human subjects provides encouraging results, wherein researchers found bone formation on implanting artificial graft material with SVF supplement compared to the graft alone [66]. The use of matrices/scaffolds and populating those with SVF and/or ADSCs is a promising area of application, though still in experimental phases [13, 78, 79]. Here, we will not go into much detail regarding the applications as that has been well accomplished in a recent two-part review [3, 26].

“Fat stem cell” therapies and regulatory scenario
Clinics all across the globe began providing “fat stem cell”-based therapy shortly after its discovery, promising miraculous results and more, but often running into controversies [80–86]. Such therapies in the US are known to charge anywhere from USD5000 to USD100,000, and, although mostly harmless and sometimes beneficial, there have been reports of vision loss, tumours, and even deaths [80–86]. Being a major issue in the USA, the FDA had to step in with a draft guideline late in 2014 [87]. These guidelines can be considered in future development of technologies and procedures related to SVF and therapies. Although the “stem cell therapy” genre includes many types of stem cells, ADSCs remain the most marketed variety in the US [88].

The common practices of enzymatic and mechanical disruption of adipose tissue for isolating SVF are explicitly mentioned in the FDA document as “more than minimal manipulation” [87]. As and when the guidelines are implemented, SVF isolated by current protocols (enzymatic digestion) can be treated as a Category 351 product, that is a “drug/biologic” and in need of complete FDA regulation [68]. This calls for exploration of alternate methods, keeping in mind that regulations in the US often trickle down to other geographies, especially in matters of food and drugs.

Introduction of the Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) Act [89] in the US Senate last year led to scientific and policy debate, with prominent organisations such as the ISCT, the International Society for Stem Cell Research (ISSCR), and many patient and advocacy groups refusing to support it, at least in its current form [88, 90–94]. The REGROW Act aims to hasten the “conditional approval” of certain cell and tissue therapeutic products which demonstrate “reasonable expectation of effectiveness” along with a few other
criteria [89]. However, the use of open-ended terms such as “reasonable expectation of effectiveness” amounts to a lack of clear scientific definition, thus leaving scope for interpretation of the law, consequently leading to potential abuse; such concerns are possibly behind this strong opposition towards the act.

Nevertheless, an urgent consensus is required among all stakeholders with regards to realising the translational potential of stem cells and other cell-based therapeutics, especially when it comes to serious unmet medical needs.

**Conclusions**

MSCs have been long known for their remarkable properties when it comes to regeneration and therapeutic potential. ADSCs are possibly the easiest to isolate among all the different types of MSCs in an adult human and in relative abundance too; up to 500 times more stem/stromal cells per gram as compared to bone marrow source [95]. Simply put, ADSCs are potentially the most abundant regenerative cells in the human body and SVF is a step in the protocol to isolate ADSCs. As has been repeatedly mentioned in this review, the potential for use of both SVF and ADSCs in regenerative medicine are immense. However, care must be taken to go about it without harming the intended beneficiary, that is the patients and public in general. Guidelines, such as the ones from US FDA and their counterparts elsewhere will be important parameters in judging new therapies and technologies being developed, and we ought to keep abreast of such issues.

| Table 3 | Major applications of SVF- and ADSC-based therapeutics with corresponding clinical trials and/or case study references |
|---------|-------------------------------------------------------------------------------------------------|
| Indications | Clinical trials (www.ClinicalTrials.gov) | Case studies and other references |
| Cosmetic applications | Breast augmentation | NCT02116933 | [14, 16, 30, 65, 68, 69] |
| | General scar, burn and wounds, facial rejuvenation, reconstruction | None found | [10, 23, 65, 70, 71] |
| | Androgenic alopecia | NCT02594046 | None found |
| Disease conditions | Vulvar lichen sclerosus | None found | [31] |
| | Erectile dysfunction | NCT02414308, NCT01601353, NCT02087397 | [67] |
| | Peyronie’s disease | NCT02414308 | None found |
| | Urinary incontinence | NCT01799694, NCT01850342 | None found |
| | Faecal incontinence | NCT02292628, NCT01011686 | None found |
| | Anal fistula | None found | [72] |
| | Multiple Sclerosis | None found | [73] |
| | Critical limb ischaemia | None found | [74, 75] |
| | Diabetic foot ulcer | NCT02394886, NCT02092870 | None found |
| | Osteoarthritis | NCT02326961 (Using Celution system) | [76] |

This Table provides an overview of major ailments in which ADSCs and SVF are being used therapeutically, with references of case studies and listed clinical trials within www.ClinicalTrials.gov [10, 14, 16, 23, 30, 31, 65–76]. For certain indications, either ClinicalTrials.gov or published cases were not found while preparing this manuscript; this may change in the future.

ADSC adipose-derived stem/stromal cell, SVF stromal vascular fraction

**Table 4 | Comparative overview of SVF and ADSCs**

| Factors | SVF | ADSCs |
|---------|-----|------|
| Cell population | Heterogeneous | Homogeneous |
| Cell type | ADSC, EC, EPC, etc. | ADSC only |
| Application range | Autologous | Autologous & allogeneic |
| Immune rejection | Not anticipated | Immune monitoring required |
| Properties | Angiogenic, immunomodulatory, and differentiative | Immunomodulatory and differentiative |
| Ex vivo exposure | Low (hours) | High (weeks) |
| Documented advantage in application | Acute myocardial infarction [9] Chronic experimental autoimmune encephalomyelitis [11] Erectile dysfunction in rat model of cavernous nerve injury [12] | Hypertrophic scars [77] |

This table provides a comparative overview of ADSCs and SVF with respect to various criteria and lists a few studies which observe advantage of one over the other [9, 11, 12, 77]

ADSC adipose-derived stem/stromal cell, EC endothelial cell, EPC endothelial precursor cell, SVF stromal vascular fraction
Technology development is the single most important factor to realise the full potential of any new therapy, and SVF-based therapy is no exception. At the same time, it is evident that we need a better understanding of SVF and ADSC biology. This is a continuous endeavour and will only help to better establish the core principles and mechanisms of SVF- and ADSC-based therapies. In the process, we are likely to discover newer applications apart from the plethora already identified. Combining these therapies with other technologies such as decellularised or three-dimensional printed scaffolds with the aim of transplantation will jump-start other areas of clinical and commercial developments.

Abbreviations
ADSC: Adipose-derived stem/stromal cell; BADSC: Brown adipose-derived stem cell; BAT: Brown adipose tissue; BM-MSC: Bone marrow mesenchymal stromal/stem cell; CAL: Cell-assisted lipotransfer; CD: Cluster of differentiation; EC: Endothelial cell; EPC: Endothelial precursor cell; FDA: Food and Drug Administration; HIF-1: Hypoxia inducible factor 1; HSC: Haematopoietic stem cell; IFATS: International Federation for Adipose Therapeutics and Science; IL: Interleukin; ISCT: International Society of Cellular Therapy; ISSCR: International Society for Stem Cell Research; MSC: Mesenchymal stem/stromal cell; PDGF: Platelet-derived growth factor; REGROW: Reliable and Effective Growth for Regenerative Health Options that Improve Wellness; SVF: Stromal vascular fraction; VEGF: Vascular endothelial growth factor; VLS: Vulvar lichen sclerosus; WAT: White adipose tissue

Acknowledgements
We thank Dr. Swathi Sundar Raj and Mr. Murali Cherat for critical reading of the manuscript and feedback, and members of Stempeutics, especially Mr. Vasanth Kumar, Ms. Pradnya Shahani, and Ms. Ankita Walvekar along with the rest of the Research & Development division for their help and support during writing of this review.

Funding
Not applicable.

Availability of data and materials
Not applicable.

Authors’ contributions
PB: Conceptualisation, data mining, and writing of manuscript. ASM: Conceptualisation, manuscript review, editing suggestions, and final approval. Both authors read and approved the final manuscript.

Competing interests
PB and ASM are or have been part of Stempeutics Research and were involved in the development of Stempeutron™ as salaried employees of Stempeutics Research Pvt. Ltd.

Consent for publication
The Tables and the Figure are original for this article and the sources used have been cited both within the article and within the Tables and Figure.

Ethics approval and consent to participate
Not applicable.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Stempeutics Research Private Limited, Akshay Tech Park, # 72/73, 2nd Floor, EPIP Zone, Phase 1, Whitefield, Bangalore 560066, India. 2Present Address: Department of Molecular Biology & Genetics, Faculty of Science, Jihoceská univerzita v Ceských Budejovicích (University of South Bohemia), Branilovská 31, 37005 Ceske Budjovice, Czech Republic.

Published online: 15 June 2017

References
1. Bourin P, Bun nell BA, Castella L, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy. 2013:15:641–8.
2. Gimble JM, Bun nell BA, Frazier T, et al. Adipose-derived stromal/stem cells. Organogenesis. 2013:9:3–10.
3. Nguyen A, Guo J, Banyard DA, et al. Stromal vascular fraction: a regenerative reality? Part 1: current concepts and review of the literature. J Plast Reconstr Aesthetic Surg. 2016:69:170–9.
4. Bun nell B, Flaat M, Gagliardi C, et al. Adipose-derived stem cells: isolation, expansion and differentiation. Methods. 2008:45:115–20.
5. Castella L. Adipose-derived stromal cells: their identity and uses in clinical trials, an update. World J Stem Cells. 2011:3:25.
6. Suzuki E, Fujita D, Takahashi M, et al. Adipose tissue-derived stem cells as a therapeutic tool for cardiovascular disease. World J Cardiol. 2015:7:454–65.
7. Bony C, Cren M, Domergue S, et al. Adipose mesenchymal stem cells isolated after manual or water-jet-assisted liposuction display similar properties. Front Immunol. 2016:6:1–8.
8. Mi HM, Sun YK, Yeon JK, et al. Human adipose tissue-derived mesenchymal stem cells improve postnatal neovascularization in a mouse model of hindlimb ischemia. Cell Physiol Biochem. 2006:17:279–93.
9. van Dijk A, Naaijens BA, Jurgens WJFM, et al. Reduction of infarct size by intravenous injection of uncultured adipose derived stromal cells in a rat model is dependent on the time point of application. Stem Cell Res. 2011:7:219–29.
10. Charles-de-Sá L, Gontijo-de-Amorim NF, Maeda Takiya C, et al. Antaging treatment of the facial skin by fat graft and adipose-derived stem cells. Plast Reconstr Surg. 2015:135:999–1009.
11. Semon JA, Zhang X, Pandey AC, et al. Administration of murine stromal vascular fraction ameliorates chronic experimental autoimmune encephalomyelitis. Stem Cells Transl Med. 2013:2:789–96.
12. You D, Jiang MJ, Kim BH, et al. Comparative study of autologous stromal vascular fraction and adipose-derived stem cells for erectile function recovery in a rat model of cavernous nerve injury. Stem Cells Transl Med. 2015:4:351–8.
13. Mohammadi R, Sanaii N, Ahsan S, et al. Stromal vascular fraction combined with silicone rubber chamber improves sciatic nerve regeneration in diabetes. Chinese J Traumatol. 2015:18:212–8.
14. Yoshimura K, Sato K, Aoi N, et al. Cell-assisted lipotransfer for cosmetic breast augmentation: supportive use of adipose-derived stromal/stem cells. Aesthetic Plastic Surg. 2008:32:48–55.
15. Pak J, Chang J-J, Lee JH, et al. Safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints. BMC Musculoskelet Disord. 2013:14:337.
16. Yoshimura K, Suga H, Eto H. Adipose-derived stem/progenitor cells roles in adipose tissue remodeling and potential use for soft tissue augmentation. Regen Med. 2009:4:265–73.
17. Matsumoto D, Sato K, Gonda K, et al. Cell-assisted lipotransfer: supportive use of human adipose-derived cells for soft tissue augmentation with lipoinjection. Tissue Eng. 2006:12:3375–82.
18. Silva FJ, Holt DJ, Vargas V, et al. Metabolically active human brown adipose tissue derived stem cells. Stem Cells. 2014:32:572–81.
19. Gimble JM, Katz AJ, Bun nell BA. Adipose-derived stem cells for regenerative medicine. Circ Res. 2007:100:1249–60.
20. Colen BD. A pill to shed fat? Harvard stem cell researchers say they finally can turn “bad” fat into “good.” Harvard Gaz 2014. https://news.harvard.edu/gazette/story/2014/12/a-pill-to-shed-fat/. Accessed 8 Sept 2016.
21. Moisan A, Lee Y-K, Zhang JD, et al. White-to-brown metabolic conversion of human adipocytes by JAK inhibition. Nat Cell Biol. 2014:16:57–67.
22. Oberbauer E, Steffenhagen C, Wuzer C, et al. Enzymatic and non-enzymatic isolation systems for adipose tissue-derived cells: current state of the art. Cell Regen. 2015:4:7.
23. Tonnard P, Verpaele A, Peeters G, et al. Nanofat grafting: basic research and clinical applications. Plast Reconstr Surg. 2013:132:1017–26.
24. Aronowitz JA, Lockhart RA, Hakakian CS. Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue. Springerplus. 2015;4:713.

25. Shah FS, Wu X, Dietrich M, et al. A non-enzymatic method for isolating human adipose tissue-derived stromal stem cells. Cytotherapy. 2013;15:979–85.

26. Guo J, Nguyen A, Banyard DA, et al. Stromal vascular fraction: a regenerative reality? Part 2: mechanisms of regenerative action. J Plast Reconstr Aesthetic Surg. 2016;69:180–80.

27. Dominici M, Le Blanc K, Mueller L, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.

28. Zulk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7:211–28.

29. SundaRaj S, Deshmukh A, Priya N, et al. Development of a system and method for automated isolation of stromal vascular fraction from adipose tissue lipoprotein. Stem Cells. Int. 2015;2015:1–11.

30. Risi S, Zachar V, Boucher S, et al. Critical steps in the isolation and expansion of adipose-derived stem cells for translational therapy. Expert Rev Mol Med. 2015;17:e32.

31. Tamburino S, Lombardo GA, Tarico MS, et al. The role of nanofat grafting in molecular and cellular healing therapies based on mesenchymal stem cells. Cell Stem Cell. 2016;18:415–31.

32. Kemaloğlu C, Onay ME, Inanc S, et al. Pericytes support neutrophil subendothelial cell crawling and breaching of venular walls in vivo. J Exp Med. 2014;213:161–73.

33. Fraser JK, Hicok KC, Shanahan R, et al. The Celution® system: automated processing of fat-derived stromal vascular cells: localization, morphology and phenotype. Adv Wound Care. 2014;3:38–45.

34. Invitrogen™ Countess™. Invitrogen cell data sheet-ADSC. http://www. thermofisher.com/content/dam/LifeTech/migration/en/filelibrary/cell-tissue- analysis/pdfs.par.71179.file.dat/co13964-stem-cell-data-sheet-adsc.pdf. Accessed 7 Sept 2016.

35. Sponsored paper. Rapid analysis of human adipose-derived stem cells and progenitor cells for vascular medicine. Stem Cells. 2011;29:1380–8.

36. Ryu YJ, Cho TJ, Lee DS, et al. Phenotypic characterization and in vivo localization of human adipose-derived mesenchymal stem cells. Mol Cells. 2013;35:557–64.

37. Asahara T, Kawamoto A, Masuda H. Concise review: circulating endothelial progenitor cells for vascular medicine. Stem Cells. 2011;29:1650–5.

38. Garipcan B, Maenz S, Pham T, et al. Image analysis of endothelial microstructure and endothelial cell dimensions of human arteries—a preliminary study. Adv Eng Mater. 2011;13:854–7.

39. Bergman RA, Affi AK, Heidger PM. Anatomy atlases: atlas of microscopic anatomy: section 4—blood. Plate 453: lymphocytes. http://www.anatomyatlases.org/MicroscopicAnatomy/Section04/Plate0453.html. Accessed 7 Sept 2016.

40. Rosenbluth MJ, Lam WA, Fletcher DA. Force microscopy of nonadherent cells: localization, morphology and phenotype. Adv Wound Care. 2014;3:38–45.

41. Scherberich A, Di Maggio N, McNagny KM. A familiar stranger: CD34 expression and putative functions in SVF cells of adipose tissue. World J Stem Cells. 2013;5:1–8.

42. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007;129:465–72.

43. Das R, Jaha H, von Osch GJW, et al. The role of hypoxia in bone marrow-derived mesenchymal stem cells: considerations for regenerative medicine approaches. Tissue Eng Part B Rev. 2010;16:159–68.

44. Eftehadifar M, Shamsaasenjan K, Movassaghpour A, et al. The effect of hypoxia on mesenchymal stem cell biology. Adv Pham Bull. 2015;45:141–9.

45. Beagle J, Lakatos K, Kalomoiris S, et al. Hypoxic preconditioning of mesenchymal stem cells induces metabolic changes, enhances survival, and promotes cell retention in vivo. Stem Cells. 2015;33:1818–28.

46. Haque N, Rahman MT, Abu Kasim NH, et al. Hypoxic culture conditions as a solution for mesenchymal stem cell based regenerative therapy. Sci World J. 2013;2013:1–12.

47. Grayson WL, Zhao F, Bunnell B, et al. Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Biochem Biophys Res Commun. 2007;358:948–53.

48. Feng Y, Zhu M, Dangelmajer S, et al. Hypoxia-cultured human adipose-derived mesenchymal stem cells are non-oncogenic and have enhanced viability, motility, and tropism to brain cancer. Cell Death Dis. 2014;5:e1567.

49. Brunet De La Grange P, Barthe C, Lippet E, et al. Oxygen concentration influences mRNA processing and expression of the CD34 gene. J Cell Biochem. 2006;97:135–44.

50. Rigotti G, Marchi A, Galie M, et al. Clinical treatment of radiotherapy tissue damage by liposarcomat transplant: a healing process mediated by adipose-derived adult stem cells. Plast Reconstr Surg. 2007;119:1409–22.

51. Prins H-J, Schulten EAJM, ten Bruggenkate CM, et al. Bone regeneration using the freshly isolated autologous stromal vascular fraction of adipose tissue in combination with calcium phosphate ceramics. Stem Cells Transl Med. 2016;5:1362–74.

52. Haahr MK, Jensen CH, Toyersenki NM, et al. Safety and potential effect of a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical trial. BJU International. 2016;204–10.

53. Tocco I, Widgerow AD, Lalezei S, et al. Lipotransfer, the potential from bench to bedside. Ann Plast Surg. 2014;72:599–609.

54. Doi K, Tanaka S, Iida H, et al. Stromal vascular fraction isolated from liposarcomas using an automated processing system: bench and bed analysis. J Tissue Eng Regen Med. 2013;7:864–70.

55. Rigotti G, Charles-de-Sá L, Gontijo-de-Amorim NF, et al. Expanded stem cells, stromal-vascular fraction, and platelet-rich plasma enriched fat: comparing results of different facial rejuvenation approaches in a clinical trial. Aesthet Surg J. 2016;36:261–70.

56. Jackson WM, Nesti LJ, Tuan RS. Concise review: clinical translation of wound healing therapies based on mesenchymal stem cells. Stem Cells Transl Med. 2012;1:44–50.

57. Borowski DW, Gill TS, Agarwal AK, et al. Autologous adipose-tissue derived regenerative cells for the treatment of complex cryptoglandular fistula-in-ano: a report of three cases. BMJ Case Rep. 2012;2012:4–7.

58. Riordan NH, Ichim TE, Min W-P, et al. Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med. 2009;7:29.

59. Lee HC, An SG, Lee HW, et al. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia. Circ J. 2012;76:1750–60.
75. Parcero JJ, Perez JA, Patel AN, et al. Autologous adipose-derived stromal stem cell implantation to resolve critical limb ischemia: case report. Cureus. 2014;6(5):e182. doi:10.7759/cureus.182. http://www.cureus.com/articles/2376-autologous-adipose-derived-stromal-stem-cell-implantation-to-resolve-critical-limb-ischemia-case-report.

76. Pers Y-M, Rackwitz L, Ferreira R, et al. Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: a phase I dose-escalation trial. Stem Cells Transl Med. 2016;5:847–56.

77. Domergue S, Bony C, Maumus M, et al. Comparison between stromal vascular fraction and adipose mesenchymal stem cells in remodeling hypertrophic scars. PLoS One. 2016;11:e0156161.

78. Frazier TP, Bowles A, Lee S, et al. Serially transplanted nonpericytic CD146+ adipose stromal/stem cells in silk bioscaffolds regenerate adipose tissue in vivo. Stem Cells. 2016;34:1097–111.

79. Lin S-D, Huang S-H, Lin Y-N, et al. Injected implant of uncultured stromal vascular fraction loaded onto a collagen gel. Ann Plast Surg. 2016;76:S108–16.

80. NEWSmax. Unregulated stem cell industry is “wild west.” NEWSmax; 2015. http://www.newsmax.com/Health/Health-News/stem-cells-treatments-regulation/2015/05/18/id/645186/. Accessed 7 Sept 2016.

81. McFarling UL. FDA moves to crack down on unproven stem cell therapies. STAT News. 2016. https://www.statnews.com/2016/02/08/fda-crackdown-stem-cell-clinics/. Accessed 7 Sept 2016.

82. Jabr F. In the flesh: the embedded dangers of untested stem cell cosmetics. Sci Am. 2012. Available at http://www.scientificamerican.com/article/stem-cell-cosmetics/. Accessed 7 Sept 2016.

83. Wilson C. Stem cell treatment causes nasal growth in woman’s back. New Sci. 2014. https://www.newscientist.com/article/dn25859-stem-cell-treatment-causes-nasal-growth-in-womans-back/. Accessed 7 Sept 2016.

84. Cyranoski D. Korean deaths spark inquiry. Nature. 2010;468:485.

85. McLean AK, Stewart C, Kemidge I. Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia. Stem Cell Res Ther. 2015;6:12.

86. Ledford H. Boom in unproven cell therapies intensifies regulatory debate. Nature. 2016;537:148.

87. US Department of Health and Human Services (Food and Drug Administration). Human cells, tissues, and cellular- and tissue-based products (HCT/Ps) from adipose tissue: regulatory considerations; draft guidance. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm427795.htm#HCT_QUESTION. Accessed 7 Sept 2016.

88. Turner L, Knoepfler P. Selling stem cells in the USA: assessing the direct-to-consumer industry. Cell Stem Cell. 2016;19:154–7.

89. Kirk MS, Manchin J, Collins SM. REGROW Act. Congress.gov 2016. https://www.congress.gov/bill/114th-congress/senate-bill/2689/cosponsors. Accessed 7 Sept 2016.

90. Research MJFF for P. MJFF signs letter opposing the REGROW Act 2016. https://www.michaeljfox.org/foundation/news-detail.php?mjff-signs-letter-opposing-the-regrow-act. Accessed 7 Sept 2016.

91. International Society for Cellular Therapy, ISCT calls for changes to proposed US REGROW Act on cell therapies 2016. http://www.celltherapysociety.org/news/news.asp?id=304128&SearchTerms=%22regrow%22. Accessed 7 Sept 2016.

92. The Alliance for Regenerative Medicine. ARM statement in response to U.S. Senator Kirk’s REGROW Act. http://alliancerm.org/sites/default/files/ARMSenatorKirk_REGROWActletter_March2016_.pdf. Accessed 7 Sept 2016.

93. Knoepfler P. California stem-cell institute’s political gamble. San Fr Chron 2016. http://www.sfchronicle.com/opinion/article/California-stem-cell-institute-s-political-8250137.php?d=10411280&h=SearchTerms=622regrow%22. Accessed 7 Sept 2016.

94. Joseph A. Drive to get more patients experimental stem cell treatments stirs concern. STAT News 2016. https://www.statnews.com/2016/06/30/stem-cell-political-fight. Accessed 7 Sept 2016.

95. Hass R, Kasper C, Bohm S, et al. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. 2011;9:12.